Efficacy of vedolizumab in fistulising Crohn’s disease: Exploratory analyses of data from GEMINI 2.

Efficacy of vedolizumab in fistulising Crohn’s disease: Exploratory analyses of data from GEMINI 2. J Crohns Colitis. 2018 Feb 17;: Authors: Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, Lasch K Abstract Background and Aims: Medical management of fistulising Crohn’s disease (CD) is constrained by the limited number of available therapies. We evaluated the efficacy of vedolizumab, a gut-selective α4β7 integrin antagonist approved for treating moderately to severely active CD, in a subpopulation of patients with fistulising CD who participated in the GEMINI 2 trial (NCT00783692).…

Read More

Differential expression of microRNAs in peripheral blood mononuclear cells identifies autophagy and TGF-beta related signatures aberrantly expressed in inflammatory bowel disease.

Differential expression of microRNAs in peripheral blood mononuclear cells identifies autophagy and TGF-beta related signatures aberrantly expressed in inflammatory bowel disease. J Crohns Colitis. 2018 Feb 06;: Authors: Mohammadi A, Kelly OB, Filice M, Kabakchiev B, Smith MI, Silverberg MS Abstract Background and Aims: MicroRNAs (miRNAs) have emerged as important regulators in inflammatory bowel disease (IBD). This study investigated differential expression of miRNAs across clinical phenotypes in a well-characterized cohort of IBD patients and healthy controls (HCs). Methods: A cohort with Crohn’s disease (CD), ulcerative colitis (UC), and HC was…

Read More

Validation of the “United Registries for Clinical Assessment and Research” (UR-CARE), a European online registry for clinical care and research in Inflammatory Bowel Disease.

Validation of the “United Registries for Clinical Assessment and Research” (UR-CARE), a European online registry for clinical care and research in Inflammatory Bowel Disease. J Crohns Colitis. 2018 Feb 03;: Authors: Burisch J, Gisbert JP, Siegmund B, Bettenworth D, Bohn Thomsen S, Cleynen I, Cremer A, Ding NJS, Furfaro F, Galanopoulos M, Grunert PC, Hanzel J, Knezevic Ivanovski T, Krustins E, Noor N, O’Morain N, Rodríguez-Lago I, Scharl M, Tua J, Uzzan M, Yassin NA, Baert F, Langholz E Abstract Background: The “United Registries for Clinical Assessment and Research” (UR-CARE)…

Read More

Microbial spectrum of intra-abdominal abscesses in perforating Crohn’s disease: Results from a prospective German Registry.

Microbial spectrum of intra-abdominal abscesses in perforating Crohn’s disease: Results from a prospective German Registry. J Crohns Colitis. 2018 Feb 05;: Authors: Reuken PA, Kruis W, Maaser C, Teich N, Büning J, Preiß JC, Schmelz R, Bruns T, Fichtner-Feigl S, Stallmach A, German IBD Study group (GISG) Abstract Background: Intra-abdominal abscesses (IAA) are common life threatening complications in patients with Crohn’s disease (CD). In addition to interventional drainage and surgical therapy, empirical antibiotic therapy represents a corner stone of treatment but contemporary data on microbial spectra and antimicrobial resistance are…

Read More

Long-Term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn’s Disease.

Long-Term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn’s Disease. J Crohns Colitis. 2018 Feb 01;: Authors: Hoekman DR, Stibbe JA, Baert FJ, Caenepeel P, Vergauwe P, De Vos M, Hommes DW, Benninga MA, Vermeire SA, D’Haens GR, BIRD (Belgian Inflammatory Bowel Disease Research and Development) Group, North-Holland Gut Club Abstract Background and Aims: Long term outcomes of early combined immunosuppression (top-down) compared to conventional management (step-up) in recently diagnosed Crohn’s disease (CD) are unknown. We aimed to investigate long-term outcomes of participants of the Step-up/Top-down-trial.…

Read More

The effect of Low Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental before-and-after Prescription Database Study.

The effect of Low Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental before-and-after Prescription Database Study. J Crohns Colitis. 2018 Jan 27;: Authors: Raknes G, Simonsen P, Småbrekke L Abstract Background and Aims: Low dose naltrexone (LDN) is a controversial off-label treatment used by many Crohn’s disease (CD) and ulcerative colitis (UC) patients. A small number of preliminary studies indicate that LDN might be beneficial in CD, but evidence is too scarce to demonstrate efficacy. We wanted to examine whether initiation of LDN therapy by patients with…

Read More

Anti-Tnf Therapeutic Drug Monitoring in Post-Operative Crohn’s Disease.

Anti-Tnf Therapeutic Drug Monitoring in Post-Operative Crohn’s Disease. J Crohns Colitis. 2018 Jan 27;: Authors: Wright EK, Kamm MA, De Cruz P, Hamilton AL, Selvaraj F, Princen F, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-Smith G, Gearry RB, Selby W, Bell SJ, Brown SJ, Connell WR Abstract Background: Anti-TNF prevents post-operative Crohn’s disease recurrence in most patients but not all. This study aimed to define the relationship between adalimumab pharmacokinetics,…

Read More

Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease.

Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease. J Crohns Colitis. 2018 Jan 29;: Authors: Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I PMID: 29385425 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29385425?dopt=Abstract

Read More

Diagnostic Yield of Dysplasia in Polyp-Adjacent Biopsies for Patients with Inflammatory Bowel Disease: A Cross-Sectional Study.

Diagnostic Yield of Dysplasia in Polyp-Adjacent Biopsies for Patients with Inflammatory Bowel Disease: A Cross-Sectional Study. J Crohns Colitis. 2018 Jan 27;: Authors: Lahiff C, Wang LM, Travis SPL, East JE Abstract Introduction: Patients with inflammatory bowel disease (IBD) undergoing polypectomy are recommended by current guidelines to have biopsies taken from adjacent mucosa to determine whether there is dysplasia present. With improvements in endoscopic imaging it is now possible to characterise colonic lesions with higher levels of confidence than previously. We reviewed the diagnostic yield of polyp-adjacent biopsies in IBD.…

Read More
<< Go Back